ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pemetrexed. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2012-01-19

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Qi WX, Tang LN, He AN, Shen Z, Yao Y.

J Cancer Res Clin Oncol · meta-analysis; research-article; systematic review; journal article · DOI 10.1007/s00432-012-1155-9

Bibliografisk träff 2012-01-13

Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.

Schuette W, Tesch H, Büttner H, Krause T, Soldatenkova V, Stoffregen C.

BMC Cancer · research-article; multicenter study; journal article; clinical trial, phase iv · DOI 10.1186/1471-2407-12-14

Bibliografisk träff 2012-01-12

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.

Bulgar AD, Weeks LD, Miao Y, Yang S, Xu Y, Guo C, Markowitz S, Oleinick N, Gerson SL, Liu L.

Cell Death Dis · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/cddis.2011.135

Bibliografisk träff 2012-01-12

A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma.

Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U, Bui-Nguyen B.

Eur J Cancer · clinical trial, phase ii; multicenter study; journal article · DOI 10.1016/j.ejca.2011.12.015

Bibliografisk träff 2012-01-06

Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.

Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S, Fukamachi T, Kobayashi H, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

Cancer Gene Ther · research support, non-u.s. gov't; journal article · DOI 10.1038/cgt.2011.86

Bibliografisk träff 2012-01-01

A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA, Greco FA.

J Thorac Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/jto.0b013e3182307efe

Bibliografisk träff 2012-01-01

Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.

Nadler E, Forsyth M, Satram-Hoang S, Reyes C.

J Thorac Oncol · research support, non-u.s. gov't; journal article · DOI 10.1097/jto.0b013e3182307f33

Bibliografisk träff 2012-01-01

Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.

Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S.

J Thorac Oncol · research support, non-u.s. gov't; journal article · DOI 10.1097/jto.0b013e3182352a45

Bibliografisk träff 2012-01-01

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA.

Pharmacoeconomics · research support, non-u.s. gov't; systematic review; journal article · DOI 10.2165/11595000-000000000-00000

Bibliografisk träff 2011-12-14

[Pemetrexed salvage chemotherapy for NSCLC: implementation study].

Jungels C, Berghmans T, Meert AP, Lafitte JJ, Scherpereel A, Sculier JP.

Rev Mal Respir · multicenter study; evaluation study; journal article · DOI 10.1016/j.rmr.2011.11.003

Bibliografisk träff 2011-11-25

Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma.

Hong T, Zhang R, Cai D, Wu X, Hua D.

J Cancer Res Clin Oncol · research-article; journal article · DOI 10.1007/s00432-011-1084-z

Bibliografisk träff 2011-10-21

Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1).

Visentin M, Chang MH, Romero MF, Zhao R, Goldman ID.

Mol Pharmacol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.111.074823

Bibliografisk träff 2011-09-19

Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

Woods B, Paracha N, Scott DA, Thatcher N.

Lung Cancer · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.lungcan.2011.07.011

Bibliografisk träff 2011-08-10

Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.

Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, Scagliotti G.

Clin Lung Cancer · multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.cllc.2011.05.007

Bibliografisk träff 2010-12-03

Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.

Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.

Eur J Radiol · journal article · DOI 10.1016/j.ejrad.2010.11.006